Tv: the place to watch the draw reside?The draw won’t be seen on typical tv, however AS has the tv sign of the occasion. So, if you would like to comply with it on display screen, you are able to do it by way of our web site and from the start of it, which will probably be, as we’ve got talked about, at 17:00.Web: how to comply with the draw online?As well as to emitting the audiovisual sign of the draw, In AS you’ll be able to comply with it with reside feedback. With us you should have the very best minute by minute, essentially the most spectacular pictures of the assembly and the statements of the protagonists, in addition to the chronicle as quickly because the video games are over. First cease of the Davis Cup Finals 2020, and that’s none apart from the draw. The teams (a complete of six, of three groups every) will probably be configured for the ultimate part of competitors that can host the Caja Mágica de Madrid between November 23 and 29. However how and the place are you able to comply with the Davis Cup Finals draw reside? Right here is the reply.Hours: what time is the Davis Cup Finals draw held?The central places of work of the ITF (Worldwide Tennis Federation) situated in London would be the scene this Thursday of the draw for the ultimate part of the Davis Cup of tennis, devised by the Kosmos group led by Gerard Piqué. The ultimate part consists of 18 groups. The draw will place them in three teams of six and there will probably be subsequent playoffs to determine the champion. The draw will begin at 17:00, Spanish time.
Angry Dhoni slams new-ball bowlers after Pune suffer another defeatAfter suffering his fifth defeat in seven Indian Premier League matches this season, MS Dhoni is certainly not a happy captain. Put into bat, Rising Pune Supergiants piled up 195 for three, courtesy Steve Smith 54-ball 101. However, they failed to defend a massive total against fellow newbies Gujarat Lions and this forced Dhoni to slam his bowlers, especially the “new-ball bowlers”.Delhi Daredevils look to exact revenge against KKRDelhi Daredevils will look to build on their hat-trick of wins when they clash with Kolkata Knight Riders in the Indian Premier League (IPL) on Saturday.Sunrisers Hyderabad aim to bounce back vs RCBSunrisers Hyderabad (SRH) would look to bounce back against a struggling Royal Challengers Bangalore (RCB) on Saturday after losing against Rising Pune Supergiants in the Indian Premier League (IPL).CAS to decide Michel Platini’s fate within 10 daysSuspended UEFA president Michel Platini said he was more optimistic of having his six-year ban from soccer overturned after his appeal hearing at sport’s highest tribunal on Friday, with a decision due within 10 days.NADA launches programme to control doping among Indian athletesThe sports ministry on Friday announced that the National Anti-Doping Agency (NADA) has launched an outreach programme to make Indian athletes aware about the pitfalls of taking substances which are prohibited by World Anti-Doping Agency (WADA).
Source:https://www.uth.edu/media/story.htm?id=37af25df-14a2-4c5e-b1ee-ac9585946aa0 May 23 2018Addressing a critical issue for people with a genetic disorder called tuberous sclerosis complex (TSC), doctors at The University of Texas Health Science Center at Houston (UTHealth) reported that a skin cream containing rapamycin significantly reduced the disfiguring facial tumors affecting more than 90 percent of people with the condition.Findings of the multicenter, international study involving 179 people with tuberous sclerosis complex appear in the journal JAMA Dermatology.”People with tuberous sclerosis complex want to look like everyone else,” said Mary Kay Koenig, M.D., the study’s lead author, co-director of the Tuberous Sclerosis Center of Excellence and holder of the Endowed Chair of Mitochondrial Medicine at McGovern Medical School at UTHealth. “And, they can with this treatment.”Tuberous sclerosis complex affects about 50,000 people in the United States and is characterized by the uncontrolled growth of non-cancerous tumors throughout the body.While benign tumors in the kidney, brain and other organs pose the greater health risk, the tumors on the face produce a greater impact on a patient’s daily life by making them look different from everyone else, Koenig said.Koenig’s team tested two compositions of facial cream containing rapamycin and a third with no rapamycin. Patients applied the cream at bedtime for six months.”Eighty percent of patients getting the study drug experienced a significant improvement compared to 25 percent of those getting the mixture with no rapamycin,” she said.”Angiofibromas on the face can be disfiguring, they can bleed and they can negatively impact quality of life for individuals with TSC,” said Kari Luther Rosbeck, president and CEO of the Tuberous Sclerosis Alliance.”Previous treatments, including laser surgery, have painful after effects. This pivotal study and publication are a huge step toward understanding the effectiveness of topical rapamycin as a treatment option. Further, it is funded by the TSC Research Program at the Department of Defense. We are so proud of this research,” Rosbeck said.Rapamycin is typically given to patients undergoing an organ transplant. When administered by mouth, rapamycin suppresses the immune system to make sure the organ is not rejected.Related StoriesEndogenous retrovirus type W found to be a major contributor to nerve damage in MSObesity linked with greater symptomatic severity of multiple sclerosisHigh levels of blood lipids may worsen multiple sclerosis symptoms in obese patientsRapamycin and tuberous sclerosis complex are linked by a protein called mTOR. When it malfunctions, tuberous sclerosis complex occurs. Rapamycin corrects this malfunction.Rapamycin was initially used successfully to treat brain tumors caused by tuberous sclerosis complex, so researchers decided to try it on TSC-related facial tumors. Building on a 2010 pilot study on the use of rapamycin to treat TSC-related facial tumors, this study confirmed that a cream containing rapamycin shrinks these tumors.As the drug’s toxicity is a concern when taken by mouth, researchers were careful to check for problems tied to its use on the skin. “It looks like the medication stays on the surface of the skin. We didn’t see any appreciable levels in the bloodstreams of those participating in the study,” Koenig said.The Topical Rapamycin to Erase Angiofibromas in TSC – Multicenter Evaluation of Novel Therapy or TREATMENT trial involved 10 test sites including one in Australia.Koenig said additional studies are needed to gauge the long-term impact of the drug, the optimal dosage and whether the facial cream should be a combined with an oral treatment.Koenig’s coauthors include Adelaide Hebert, M.D.; Joshua Samuels, M.D., M.P.H.; John Slopis, M.D.; Cynthia S. Bell; Joan Roberson, R.N.; Patti Tate; and Hope Northrup, M.D. All are from McGovern Medical School at UTHealth with the exception of Slopis, who is with The University of Texas MD Anderson Cancer Center. Hebert is also on the faculty of the MD Anderson Cancer Center and Northrup on the faculty of The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences. The study was supported in part by the United States Department of Defense grant DOD TSCRP CDMRP W81XWH-11-1-0240 and by the Tuberous Sclerosis Alliance of Australia.”The face is our window to the world and when you look different from everyone else, it impacts your confidence and your ability to interact with others. This treatment will help those with TSC become more like everyone else,” Koenig said.